<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">787</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2025-12-2-77-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of proline P325 residue in the recognition of the MX35 epitope of the sodium-dependent phosphate transporter NaPi2b by monoclonal antibodies in ovarian carcinoma cells</article-title><trans-title-group xml:lang="ru"><trans-title>Роль остатка пролина Р325 в распознавании эпитопа MX35 натрийзависимого фосфатного транспортера NaPi2b моноклональными антителами в клетках карциномы яичника</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6696-8477</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulatova</surname><given-names>L. F.</given-names></name><name xml:lang="ru"><surname>Булатова</surname><given-names>Л. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 1, 18 Kremlevskaya St.; Kazan 420008</p></bio><bio xml:lang="ru"><p>420008 Казань, ул. Кремлевская, 18, корп. 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-6709-1010</contrib-id><name-alternatives><name xml:lang="en"><surname>Slidzuk</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Слидзюк</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 1, 18 Kremlevskaya St.; Kazan 420008</p></bio><bio xml:lang="ru"><p>420008 Казань, ул. Кремлевская, 18, корп. 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-2262-4200</contrib-id><name-alternatives><name xml:lang="en"><surname>Kilunov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Килунов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 1, 18 Kremlevskaya St.; Kazan 420008</p></bio><bio xml:lang="ru"><p>420008 Казань, ул. Кремлевская, 18, корп. 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6342-0390</contrib-id><name-alternatives><name xml:lang="en"><surname>Skripova</surname><given-names>V. S.</given-names></name><name xml:lang="ru"><surname>Скрипова</surname><given-names>В. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 1, 18 Kremlevskaya St.; Kazan 420008</p></bio><bio xml:lang="ru"><p>420008 Казань, ул. Кремлевская, 18, корп. 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2547-2843</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiyamova</surname><given-names>R. G.</given-names></name><name xml:lang="ru"><surname>Киямова</surname><given-names>Р. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ramziya Gallyamovna Kiyamova</p><p>Bld. 1, 18 Kremlevskaya St.; Kazan 420008</p></bio><bio xml:lang="ru"><p>Рамзия Галлямовна Киямова</p><p>420008 Казань, ул. Кремлевская, 18, корп. 1</p></bio><email>kiyamova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Laboratory “Biomarker”, Institute of Fundamental Medicine and Biology of the Kazan Federal University</institution></aff><aff><institution xml:lang="ru">Научно-исследовательская лаборатория «Биомаркер», Институт фундаментальной медицины и биологии ФГАОУ ВО «Казанский (Приволжский) федеральный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>77</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2025-06-28"><day>28</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-28"><day>28</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Bulatova L.F., Slidzuk I.A., Kilunov A.V., Skripova V.S., Kiyamova R.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Булатова Л.Ф., Слидзюк И.А., Килунов А.В., Скрипова В.С., Киямова Р.Г.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Bulatova L.F., Slidzuk I.A., Kilunov A.V., Skripova V.S., Kiyamova R.G.</copyright-holder><copyright-holder xml:lang="ru">Булатова Л.Ф., Слидзюк И.А., Килунов А.В., Скрипова В.С., Киямова Р.Г.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/787">https://umo.abvpress.ru/jour/article/view/787</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. One of the key components of cell membranes are membrane proteins, which provide a wide range of functions – from transport and signal transmission to coordination of intercellular interactions. Among them, of particular interest is the sodium-dependent phosphate transporter NaPi2b, which plays an important role in maintaining phosphate homeostasis and is characterized by an increased content in a number of tumor cells. The large extracellular domain (ECD) of NaPi2b contains the MX35 epitope, which is of significant interest in the context of the development of monoclonal antibodies for targeted therapy of ovarian and lung carcinoma. Recognition of the MX35 epitope depends on the conformation of the large ECD, which is influenced by disulfide bonds and glycosylation. Between cysteine residues C322 and C328, there is a proline residue P325, which we hypothesize may contribute to the conformation of the NaPi2b large ECD by forming a disulfide bond between C322 and C328, potentially affecting the interaction of monoclonal antibodies with the MX35 epitope.</p><p><bold>Aim</bold>. To study the impact of the proline residue at position 325 in the large ECD of the transporter NaPi2b on the interaction of monoclonal antibodies L3(28/1) with the MX35 epitope.</p><p><bold>Materials and methods.</bold> The human ovarian epithelial carcinoma cell lines OVCAR-8 and OVCAR-4 were used in the study. By site-directed mutagenesis, the proline residue P325 of NaPi2b was replaced with an alanine residue, resulting in OVCAR-8 cells stably expressing the mutant variant of NaPi2bp.P325A. The effect of the p.P325A substitution in NaPi2b on the interaction of monoclonal antibodies L3(28/1) with the MX35 epitope was analyzed using western blotting and laser confocal microscopy. To assess the impact of the p.P325A mutation on the formation of disulfide bonds in the NaPi2b large ECD, cysteine residues thiol groups were modified using maleimide-containing compounds.</p><p><bold>Results</bold>. It was found that the substitution of p.P325A in NaPi2b did not significantly affect the recognition of the MX35 epitope by L3(28/1) antibodies, as shown by both western blot analysis and confocal microscopy. The number of disulfide bonds in the large ECD of the mutant NaPi2bp.P325A form was unchanged compared to wild-type NaPi2b.</p><p><bold>Conclusion</bold>. Substitution p.P325A in the NaPi2b transporter does not have a significant effect on the recognition of the MX35 epitope by antibodies or the formation of disulfide bonds in the NaPi2b large ECD. Future studies could focus on a more detailed investigation of the roles of other substitutions in the NaPi2b large ECD and their influence on the epitope’s accessibility to antibodies.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Одним из ключевых компонентов клеточных мембран являются мембранные белки, обеспечивающие широкий спектр функций – от транспорта и передачи сигналов до координации межклеточных взаимодействий. Среди них особый интерес представляет натрийзависимый фосфатный транспортер NaPi2b, играющий большую роль в поддержании гомеостаза фосфатов и содержащийся в большом количестве в ряде опухолевых клеток. В состав большого внеклеточного домена (ВКД) NaPi2b входит эпитоп MX35, который представляет значительный интерес в контексте разработки моноклональных антител для таргетной терапии карциномы яичника и легкого. Рас познавание эпитопа MX35 зависит от конформации большого ВкД, обусловленной дисульфидными связями и гликозилированием. Между двумя остатками цистеина – С322 и С328 – находится остаток пролина P325, который, как мы предполагаем, может участвовать в формировании конформации большого ВКД NaPi2b посредством образования дисульфидной связи С322–С328, влияющей на взаимодействие моноклональных антител и эпитопа MX35.</p><p><bold>Цель исследования</bold> – изучение влияния остатка пролина в положении 325 в области большого ВКД транспортера NaPi2b на взаимодействие моноклональных антител L3(28/1) с эпитопом MX35.</p><p><bold>Материалы и методы</bold>. В исследовании использованы клеточные линии эпителиальной карциномы яичника чело века OVCAR-8 и OVCAR-4. путем сайт-направленного мутагенеза остаток пролина P325 NaPi2b заменили на остаток аланина, в результате чего были получены клетки OVCAR-8, стабильно экспрессирующие мутантный вариант NaPi2bp.P325A. С помощью вестерн-блот-анализа и лазерной конфокальной микроскопии изучено влияние замены p.P325A NaPi2b на взаимодействие моноклональных антител L3(28/1) и эпитопа МХ35. Для определения влияния мутации p.P325A на формирование дисульфидных связей в большом ВКД NaPi2b проводили модификацию тиоловых групп остатков цистеина с использованием малеимидсодержащих соединений.</p><p><bold>Результаты</bold>. Выявлено, что замена p.P325A NaPi2b не оказывает значительного влияния на распознавание эпитопа MX35 антителами L3(28/1) как при вестерн-блот-анализе, так и при конфокальной микроскопии. количество дисульфидных связей в большом ВКД NaPi2bp.P325A не менялось по сравнению с NaPi2b дикого типа.</p><p><bold>Заключение</bold>. Замена p.P325A транспортера NaPi2b не оказывает значимого влияния на распознавание эпитопа MX35 антителами и формирование дисульфидных связей в большом ВКД NaPi2b. Дальнейшие исследования могут быть направлены на более детальное изучение роли других замен в большом ВКД NaPi2b и их влияния на доступность эпитопа для антител.</p></trans-abstract><kwd-group xml:lang="en"><kwd>NaPi2b</kwd><kwd>MX35 epitope</kwd><kwd>proline residue P325</kwd><kwd>monoclonal antibody</kwd><kwd>ovarian carcinoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>NaPi2b</kwd><kwd>эпитоп MX35</kwd><kwd>остаток пролина P325</kwd><kwd>моноклональное антитело</kwd><kwd>карцинома яичника</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was supported by the Russian Science Foundation grant (grant No. 23-15-00456, https://rscf.ru/project/23-15-00456/).</funding-statement><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда (грант № 23-15-00456, https://rscf.ru/project/23-15-00456/).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Guo L., Wang S., Li M., Cao Z. Accurate classification of membrane protein types based on sequence and evolutionary information using deep learning. BMC Bioinformatics 2019;20:1–17. DOI: 10.1186/s12859-019-3275-6</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Krogh A., Larsson B., Von Heijne G., Sonnhammer E.L. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001;305(3):567–80. DOI: 10.1006/jmbi.2000.4315</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993–6. DOI: 10.1038/nrd2199</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Forster I.C. The molecular mechanism of SLC34 proteins: insights from two decades of transport assays and structure-function studies. Pflügers Arch 2019;471(Pt 2):15–42. DOI: 10.1007/s00424-018-2207-z</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bulatova L., Savenkova D., Nurgalieva A. et al. Toward a topology based therapeutic design of membrane proteins: validation of NaPi2b topology in live ovarian cancer cells. Front Mol Biosci 2022;9:895911. DOI: 10.3389/fmolb.2022.895911</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Vlasenkova R., Nurgalieva A., Akberova N. et al. Characterization of SLC34A2 as a potential prognostic marker of oncological diseases. Biomolecules 2021;11(12):1878. DOI: 10.3390/biom11121878</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Soares I.C., Simões K., de Souza J.E.S. et al. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody MX35. Appl Immunohistochem Mol Morphol 2012;20(2):165–72. DOI: 10.1097/pai.0b013e318228e232</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kiyamova R., Shyian M., Lyzogubov V.V. et al. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. Exp Oncol 2011;33(3):157–61.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gryshkova V., Goncharuk I., Gurtovyy V. et al. The study of phosphate transporter NaPi2b expression in different histological types of epithelial ovarian cancer. Exp Oncol 2009;31(1):37–42.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Rangel L.B.A., Sherman-Baust C.A., Wernyj R.P. et al. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene 2003;22(46):7225–32. DOI: 10.1038/sj.onc.1207008</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yin B.W.T., Kiyamova R., Chua R. et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun 2008;8:3.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Horsley E., Jabeen A., Veillard N. et al. Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b. Cancer Res 2024;84(6_Suppl):5085. DOI: 10.1158/1538-7445.AM2024-5085</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fessler S., Dirksen A., Collins S.D. et al. XMT-1592, a site-specific dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma. Cancer Res 2020;80(16_Suppl):2894. DOI: 10.1158/1538-7445.am2020-2894</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kiyamova R., Minigulova L.F., Skripova V. et al. N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells. Ann Oncol 2020;31(5):S1227–8. DOI: 10.1016/j.annonc.2020.08.2193</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Korotaeva A.V., Bulatova L.F., Vlasenkova R.A., Kiyamova R.G. Recognition of the Na-dependent phosphate transporter NaPi2b by monoclonal antibodies in bacterial and eukaryotic cells. Biotekhnologiya = Biotechnology 2022;38(5):66–72. (In Russ.). DOI: 10.56304/S023427582205009X</mixed-citation><mixed-citation xml:lang="ru">Коротаева А.В., Булатова Л.Ф., Власенкова Р.А., Киямова Р.Г. Распознавание Na-зависимого фосфатного транспортера NaPi2b моноклональными антителами в клетках бактерий и эукариот. Биотехнология 2022;38(5):66–72.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Minigulova L.F., Skripova V.S., Nurgalieva A.K. et al. Recognition of the sodium-dependent phosphate transporter NaPi2b by monoclonal antibodies N-NaPi2b in ovarian cancer cells. Uchenye zapiski Kazanskogo universiteta = Academic notes of Kazan University 2020;162(4):529–40. (In Russ.). DOI: 10.26907/2542-064X.2020.4.529-540</mixed-citation><mixed-citation xml:lang="ru">Минигулова Л.Ф., Скрипова В.С., Нургалиева А.К. и др. Распознавание натрийзависимого фосфатного транспортера NaPi2b моноклональными антителами N-NaPi2b в клетках карциномы яичника. Ученые записки Казанского университета 2020;162(4):529–40. DOI: 10.26907/2542-064X.2020.4.529-540</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Gryshkova V., Lituiev D., Savinska L. et al. Generation of monoclonal antibodies against tumor-associated antigen MX35 sodium-dependent phosphate transporter NaPi2b. Hybridoma (Larchmt) 2011;30(1):37–42. DOI: 10.1089/hyb.2010.0064</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bulatova L.F., Skripova V.S., Nurgalieva A.K. et al. Structurally constrained tumor-specific epitope within the largest extracellular domain of sodium-dependent phosphate transporter NaPi2b. Ann Oncol 2021;32(5):S368–9. DOI: 10.1016/j.annonc.2021.08.304</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Bulatova L.F., Skripova V.S., Korotaeva A.V. et al. Recognition of mutant forms of the sodium-dependent phosphate transporter NaPi2b by monoclonal antibodies in ovarian cancer cells. Kazanskiy meditsinskiy zhurnal = Kazan medical journal 2022;103(4):608–16. (In Russ.). DOI: 10.17816/KMJ2022-608</mixed-citation><mixed-citation xml:lang="ru">Булатова Л.Ф., Скрипова В.С., Коротаева А.В. и др. Распознавание мутантных форм натрийзависимого фосфатного транс портера NaPi2b моноклональными антителами в клетках рака яичника. Казанский медицинский журнал 2022;103(4):608–16. DOI: 10.17816/KMJ2022-608</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Nadeau V.G., Deber C.M. Structural impact of proline mutations in the loop region of an ancestral membrane protein. Biopolymers 2016;106(1):37–42. DOI: 10.1002/bip.22765</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kiyamova R., Gryshkova V., Ovcharenko G. et al. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. Hybridoma 2008;27(4):277–84. DOI: 10.1089/hyb.2008.0015</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Boichuk S., Dunaev P., Skripova V. et al. Unraveling the mechanisms of sensitivity to anti-FGF therapies in imatinib resistant gastrointestinal stromal tumors (GIST) lacking secondary KIT mutations. Cancers (Basel) 2023;15(22):5354. DOI: 10.3390/cancers15225354.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>McKinnon L.J., Fukushima J., Endow J.K. et al. Membrane chaperoning of a thylakoid protease whose structural stability is modified by the protonmotive force. Plant Cell 2020;32(5):1589–609. DOI: 10.1105/tpc.19.00797</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Krieger F., Möglich A., Kiefhaber T. Effect of proline and glycine residues on dynamics and barriers of loop formation in polypeptide chains. J Am Chem Soc 2005;127(10):3346–52. DOI: 10.1021/ja042798i</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Schmitt S., Mai I., Machui P. et al. TUB-040, a novel Napi2b targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans. Cancer Res 2024; 84(6_Suppl):2622. DOI: 10.1158/1538-7445.AM2024-2622</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Gryshkova V.S., Filonenko V.V., Kiyamova R.G. Inhibition of sodium-dependent phosphate transporter NaPi2b function with MX35 antibody. Biopolym Cell 2011;27:193–8. DOI: 10.7124/bc.0000B9</mixed-citation></ref></ref-list></back></article>
